JP Morgan Chase
NTLA icon

JP Morgan Chase’s Intellia Therapeutics NTLA Stock Holding History

JP Morgan Chase’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,600
Closed -$79.4K – 7662
2025
Q3 		$79.4K Buy
+4,600
New +$56.7K ﹤0.01% 6035
2025
Q1 		– Sell
-20,400
Closed -$238K – 7612
2024
Q4 		$238K Buy
+20,400
New +$318K ﹤0.01% 5404

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

JP Morgan Chase's NTLA Position: Q2 2026 in Review

JP Morgan Chase reduced its Intellia Therapeutics (NTLA) stake by 3.8% in Q2 2026, selling an estimated $292K and leaving 527,662 shares worth $8.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

JP Morgan Chase first reported a position in NTLA in Q2 2016 and has held it in 37 quarters since. The position peaked at $145M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • JP Morgan Chase held 527,662 shares of Intellia Therapeutics worth $8.87M as of Q2 2026.
  • JP Morgan Chase sold 20,829 Intellia Therapeutics shares in Q2 2026, an estimated $292K.
  • Intellia Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2911 holding.
  • JP Morgan Chase first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 37 quarters since.
  • JP Morgan Chase's Intellia Therapeutics position peaked at $145M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.